Ovarian cancer (OC) is the second most common form of gynecological cancer and is the most fatal among all forms of gynecological malignancies. Despite the important role of metabolic processes in the molecular pathogenesis of OC, robust metabolic markers to enable effective screening, rapid diagnosis, accurate surveillance, and therapeutic monitoring of OC are still lacking. In this study, we present a targeted liquid chromatography‐tandem mass spectrometry (LC‐MS/MS)‐based metabolic profiling approach for the identification of metabolic biomarker candidates that could enable expedited, highly sensitive and specific OC detection. Using this targeted approach, 90 plasma metabolites from many metabolic pathways of potential biological significance were reliably detected and monitored in 218 samples taken from the three groups of subjects (78 OC patients, 50 benign samples, and 90 healthy controls). Multivariate significance testing and receiver operating characteristic (ROC) analysis revealed 8 significant metabolites (p2) and high predictive accuracy [area under the curve (AUC)>0.90] for distinguishing healthy controls from OC patients. For discrimination of OC patients from benign samples, the results of our model refinement pipeline informed the construction of a logistic regression classifier defined by a 5‐metbaolite panel of potential plasma biomarkers, exhibiting roughly 75% predictive accuracy using a 50% random‐split training and testing paradigm for external validation. Multivariate ROC analysis showed enhanced classification performance for identification of OC patients from benign samples, relative to individual metabolites. Pathway analysis revealed significant disturbances in glycine, serine, and threonine metabolism; glyoxylate and dioxylate metabolism; the pentose phosphate pathway; and histidine metabolism. The results expand basic knowledge of the metabolome related to OC pathogenesis relative to both healthy and benign samples, revealing potential pathways or markers that can be targeted therapeutically. This study also provides a promising basis for the development of larger multi‐site projects to validate our findings across population groups and further advances the development of improved clinical care for OC patients.
Alzheimer’s disease (AD) is the most common cause of dementia, accounting for an estimated 60 to 80% of cases, and is the sixth‐leading cause of death in the United States. A major challenge persists in the post‐mortem diagnosis of AD patients from those suffering mild cognitive impairment (MCI) and control patients with high pathology (HPC). Mass spectrometry (MS)‐based metabolomics has shown significant potential in disease diagnosis over the past two decades. In this study, we present a combination of gas chromatography‐MS (GC‐MS) for global metabolic profiling and analysis of long‐ and short‐chain fatty acids, in addition to liquid chromatography‐tandem MS (LC‐MS/MS) for the detection of targeted aqueous metabolites and lipids. Using this approach, 2084 metabolites and features were reliably detected and monitored in 48 tissue samples harvested from the superior frontal gyrus of male and female subjects post‐mortem. Samples were taken from four groups: 12 normal control (NC) patients, 12 subjects characterized as HPC, 12 with sub‐clinical MCI, and 12 diagnosed with AD. Multivariate significance testing informed the construction and cross‐validation (p < 0.05) of partial least squares‐discriminant analysis (PLS‐DA) models defined by a 9‐metabolite panel of potential diagnostic biomarkers. Receiver operating characteristic (ROC) analysis showed high predictive accuracy of the resulting PLS‐DA models for discrimination of NC (96.6%), HPC (91.7%), MCI (93.9%) and AD (95.1%). Pathway analysis revealed significant disturbances in lysine degradation (p = 0.007), fatty acid metabolism (p = 0.009), and the degradation of branched‐chain amino acids (p = 0.025). Over representation analysis of lipid signatures revealed significant alterations in glycerophospholipid (FDR q = 8.3E‐07) and choline metabolism (FDR q = 0.006). Network analysis showed significant enrichment in 11 enzymes, mostly of the mitochondria. The current results allow for improved clinical staging post‐mortem, expand basic knowledge of the metabolome related to AD pathogenesis, and reveal pathways that can be targeted therapeutically in future studies. This study also provides a promising basis for the development of larger multi‐site projects to validate these candidate markers in readily available biospecimens such as blood to enable the effective screening, rapid diagnosis, accurate surveillance, and therapeutic monitoring of AD across population groups. Support or Funding Information: Support from the College of Health Solutions at Arizona State University and the National Institutes of Health is gratefully acknowledged.